OncoHost

02/02/2026

Thank you MLO - Medical Laboratory Observer for featuring our recent win in the 2025 ! We’re honored to be recognized for our efforts and remain dedicated to driving progress in precision oncology.

Read the full article here: https://bit.ly/46eblo2

OncoHost has been honored with the 2026 BIG Innovation Award in the Health category and named a Top 10 Small Business Innovator for its PROphet platform, an AI-powered plasma-...

01/29/2026

🧬PROphet is being recognized in a peer-reviewed biomarker landscape for metastatic !

In the review, PROphet is benchmarked in the top-tier evidence bracket across modalities with a score of 14 - the highest among proteomic & genomic predictors of poor ICI response in NSCLC reviewed.
Score 14 reflects the highest rating of consistency, statistical validity, relevant endpoint, confounder adjustment, external validation, large cohort, and data availability.

📄Scan the QR code below ro read the full report.

01/27/2026

When “more” isn’t better, biology matters.

New real-world evidence challenges a long-standing assumption in PD-L1 ≥50% NSCLC: that high tumor burden justifies upfront chemo-IO.

A new study shows that despite expert opinion referenced in American Society of Clinical Oncology (ASCO) guidelines, adding chemotherapy to pembrolizumab did not improve survival—even in patients with aggressive disease features—and came with significantly higher toxicity and hospitalizations.

Key takeaways:
• High tumor burden and large baseline lesions did not predict benefit from chemo-IO
• “Debulking” with chemotherapy did not enhance IO outcomes in PD-L1 ≥50% disease
• Clinical features alone failed to identify who truly benefits from treatment escalation

This isn’t about telling clinicians what to do. It’s about recognizing that exceptional cases shouldn’t become default practice - and that escalation decisions deserve more than surface-level clinical proxies.

As more commonly cited biomarkers fall short, the signal is clear:
👉 Clinical features are not enough. Biology matters.

That’s exactly where biology-based, host-response insights can add value - helping identify upfront who can do well on IO alone, and who may truly need intensification.

📄 Read the study: https://journals.sagepub.com/doi/10.1177/17588359251396266

Background: Pembrolizumab plus chemotherapy (Pembrolizumab-CT) has been suggested as first-line treatment over pembrolizumab alone in aggressive non-small-cell ...

01/25/2026

OncoHost is on the ground in Miami 🌴

Our Chief Commercial Officer and Director of Scientific Affairs are attending the Annual Winter Lung Cancer Conference in Miami Beach, engaging with the lung cancer community on the clinical and scientific questions shaping next-generation care.

From first-line decision-making to the evolving role of host-response biology, this meeting is where real-world insights meet real clinical needs. We’re here to listen, exchange perspectives, and continue advancing smarter, biology-driven precision oncology.

01/22/2026

📄🧬PROphet is being recognized in a peer-reviewed biomarker landscape for metastatic !

This is the direction the field is moving: integrated decision support - using systemic biology to complement tumor-only markers, and helping clinicians plan with more confidence.

Read the full review here: https://bit.ly/4pUlddQ

This link will take you to a page that’s not on LinkedIn

01/15/2026

🏆 Award news! OncoHost has been named a 2026 BIG Innovation Awards winner (Health category) — and recognized as a Top 10 Innovator – Small Business.

This recognition highlights the growing momentum behind PROphet®, our AI-driven, plasma-proteomics platform designed to bring actionable insights into real-world oncology decision-making.

By capturing the patient’s host-response biology from a single pre-treatment blood sample, PROphet® helps physicians:
✅ avoid ineffective treatment
✅ reduce unnecessary toxicity
✅ choose the right therapy for the right patient — from day one

A huge thank you to the Business Intelligence Group for this honor — and to our incredible team and partners who are helping advance a future where every cancer treatment begins with precision.

Read the full release here: https://prn.to/4bAm8fL

/PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, announced today that it has been...

01/12/2026

We’re proud to share our latest thought leadership in The Cancer Letter : “Composite intelligence: How AI-driven biomarkers are setting the bar in immuno-oncology.”

Featuring Ofer Sharon, MD (CEO), Michal Harel, PhD (VP Translational Medicine), and Yehonatan Elon, PhD (CTO), the piece makes a clear case for what’s next in IO decision-making: moving from single-marker snapshots to AI-powered composite biomarkers that integrate tumor signals and host response - because immunotherapy outcomes are shaped by both.

Read the full article here: https://bit.ly/45Qmmf0

A new chapter for immunotherapy decision-making Immune-checkpoint inhibitors (ICIs) transformed treatment paradigms in dozens of malignancies, yet oncologists still confront a deceptively simple question at every consult: Will this individual patient benefit and at what cost?  Conventional, tumor c...

01/08/2026

🚀 Precision oncology is no longer just the future - it’s here today.
At OncoHost, we’re combining proteomics + AI to give oncologists the actionable insights they need, right when it matters most.

Because every treatment decision reshapes a future.

👉 Learn how PROphet® is amplifying oncologists’ expertise and changing the conversation in cancer care.
https://bit.ly/4cgNODS

Explore OncoHost's PROphet Technology, a cutting-edge precision oncology platform driving advancements in biomarkers for cancer treatment decisions.

01/01/2026

Thank you to Biotechgate for spotlighting our Gold win in the 2025 Merit Awards for Healthcare!

A proud moment for our team - and an important signal that host-response, blood-based precision medicine is gaining the visibility (and momentum) it deserves.

Read the coverage 👇
https://bit.ly/3MWxzEt

12/29/2025

In advanced , first-line decisions are rarely one-dimensional.
PROphetNSCLC® is a blood-based test that delivers host-response insights to consider alongside tumor biomarkers and clinical factors—helping care teams add a deeper layer of confidence when selecting first-line therapy.

Because smarter decisions don’t come from one signal - they come from the full picture.

https://www.oncohost.com/product-nsclc

Learn about OncoHost's PROphetNSCLC Test, a breakthrough in precision oncology for non-small cell lung cancer, guiding personalized treatment.

12/24/2025

As the year comes to a close, we celebrate the progress made together and the milestones achieved. Thank you for being an invaluable part of our journey.

Here’s to continuing our work together, turning challenges into opportunities, and advancing care for patients worldwide.

Wishing you and your loved ones a joyful holiday season and a healthy, prosperous New Year.

Warmest wishes from all of us at OncoHost! 🎄✨

#2026

12/22/2025

📄🧬PROphet is being recognized in the peer-reviewed biomarker landscape for metastatic NSCLC

A recently published review in Lung Cancer: Targets and Therapy (DovePress / Dove Medical Press) highlights blood-based proteomic predictors of immune checkpoint inhibitor (ICI) response - and specifically calls out PROphet as a multi-analyte platform with clinical planning value.

In the review, PROphet is benchmarked in the top-tier evidence bracket across modalities with a score of 14 - the highest among proteomic & genomic predictors of poor ICI response in NSCLC reviewed (table 5). Score 14 reflects the highest rating of consistency, statistical validity, relevant endpoint, confounder adjustment, external validation, large cohort, and data availability.

Notable excerpts from the review:

- “Multi-analyte platforms such as PROphet demonstrated promising risk-stratification potential.”
- “Blood-based proteomic platforms such as PROphet… have shown value alongside PD-L1 testing for treatment planning in metastatic NSCLC.”
- “A machine learning–based proteomic test termed PROphet… derived from 388 proteins, stratified patients into groups with differential benefit,” spanning immune regulatory and stromal pathways—reflecting systemic influences on immunotherapy efficacy.

This is the direction the field is moving: integrated decision support - using systemic biology to complement tumor-only markers, and helping clinicians plan with more confidence.

Read the full review here: https://www.dovepress.com/article/download/109957